Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$6.96 USD
-0.26 (-3.60%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $6.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 1 - 20 ( 180 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Solid Quarter for Zurzuvae, But Dalzanemdor Sees Endpoint Shift; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zurzuvae Moving Along As We Await Dalzanemdor Updates In Late-2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
ET KOL Check: Delving Into The Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
KINETIC2 in Essential Tremor Misses; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
KINETIC 2 Fails To Meet Endpoint; SAGE-324 Development Halted
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
INVITE: ET KOL Call - Delving Into The Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Takeaways From Our Conversation With Sage Management; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
SURVEYOR Offers a Signal, But More is Needed; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
SURVEYOR Data Arrives, But Limited Disclosures While DIMENSION Continues
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Survey Says... PPD Opportunity There, But Likely Going To Take Time To Build
Provider: Wedbush Securities Inc.
Analyst: CHICO L